Pharmacokinetic Study of Continuous Infusion of Remazolam in Mechanically Ventilated Patients in ICU
NCT ID: NCT05480787
Last Updated: 2022-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
30 participants
INTERVENTIONAL
2022-02-01
2022-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Compatible Effect of Remimazolam Besylate Combined With Afentanil for ATI
NCT06026566
Effect of Remimazolam With Protocolized Sedation on Critical Ill, Mechanical Ventilated Patients Compared With Midazolam
NCT05160987
Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients
NCT06575530
Remimazolam for Sedation in ICU Patients Undergoing Mechanical Ventilation
NCT04815265
PK/PD Properties and Safety of Remazolam Besylate for Injection in ICU Patients With Impaired Renal Function
NCT06153498
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Remimazolam 0.1mg/kg/h
Participants were first induced with 5mg in 1-min intravenous injection and then maintained at 0.1 mg/kg/h.
Remimazolam 0.1mg/kg/h
Remimazolam Tosilate for Injection(36mg)
Remimazolam 0.3mg/kg/h
Participants were first induced with 5mg in 1-min intravenous injection and then maintained at 0.3 mg/kg/h.
Remimazolam 0.3mg/kg/h
Remimazolam Tosilate for Injection(36mg)
Remimazolam 0.5mg/kg/h
Participants were first induced with 5mg in 1-min intravenous injection and then maintained at 0.5 mg/kg/h.
Remimazolam 0.5mg/kg/h
Remimazolam Tosilate for Injection(36mg)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Remimazolam 0.1mg/kg/h
Remimazolam Tosilate for Injection(36mg)
Remimazolam 0.3mg/kg/h
Remimazolam Tosilate for Injection(36mg)
Remimazolam 0.5mg/kg/h
Remimazolam Tosilate for Injection(36mg)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Affiliated Hospital with Nanjing Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hu J, Zhao Y, Shao L, Zhang W, Wang H, Liu Y, Su M, Zuo X. Pharmacokinetic Properties and Therapeutic Effectiveness of Remimazolam in ICU Patients With Mechanical Ventilation: A Preliminary Study. Pharmacol Res Perspect. 2025 Jun;13(3):e70130. doi: 10.1002/prp2.70130.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020120989remimazolam
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.